Status:
COMPLETED
Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Schizophrenia
Eligibility:
MALE
21-55 years
Phase:
PHASE2
Brief Summary
This study is to evaluate the safety and efficacy of the study drug compared to placebo in the treatment of cognitive impairment in men with schizophrenia.
Eligibility Criteria
Inclusion
- Patient is male between 21 and 55 years of age
- Duration of the illness must be longer than 1 year
- Patient's current antipsychotic medication regimen must be stable
- Patient is negative for selected drugs of abuse at Screening
- Must be in a stable living arrangement for at least 3 months prior to screening (not a homeless shelter)
Exclusion
- Patient has mental retardation
- Undergone Electroconvulsive Therapy (ECT) treatment within 6 months prior to screening
- Has suicidal attempts or ideation within the last 12 months
- Patient has a history of alcohol/drug dependence within 1 year or alcohol/drug abuse within 12 months of starting the study
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT00848484
Start Date
October 1 2008
End Date
June 1 2009
Last Update
November 2 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.